Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Erythropoietin : a candidate treatment for mood symptoms and memory dysfunction in depression. / Miskowiak, Kamilla W; Vinberg, Maj; Harmer, Catherine J; Ehrenreich, Hannelore; Kessing, Lars V.

I: Psychopharmacology, Bind 219, Nr. 3, 2012, s. 687-98.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Miskowiak, KW, Vinberg, M, Harmer, CJ, Ehrenreich, H & Kessing, LV 2012, 'Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression', Psychopharmacology, bind 219, nr. 3, s. 687-98. https://doi.org/10.1007/s00213-011-2511-1

APA

Miskowiak, K. W., Vinberg, M., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2012). Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology, 219(3), 687-98. https://doi.org/10.1007/s00213-011-2511-1

Vancouver

Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Kessing LV. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology. 2012;219(3):687-98. https://doi.org/10.1007/s00213-011-2511-1

Author

Miskowiak, Kamilla W ; Vinberg, Maj ; Harmer, Catherine J ; Ehrenreich, Hannelore ; Kessing, Lars V. / Erythropoietin : a candidate treatment for mood symptoms and memory dysfunction in depression. I: Psychopharmacology. 2012 ; Bind 219, Nr. 3. s. 687-98.

Bibtex

@article{db44bbf6be8646afb0331d5e0022a3ec,
title = "Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression",
abstract = "Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.",
author = "Miskowiak, {Kamilla W} and Maj Vinberg and Harmer, {Catherine J} and Hannelore Ehrenreich and Kessing, {Lars V}",
year = "2012",
doi = "10.1007/s00213-011-2511-1",
language = "English",
volume = "219",
pages = "687--98",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Erythropoietin

T2 - a candidate treatment for mood symptoms and memory dysfunction in depression

AU - Miskowiak, Kamilla W

AU - Vinberg, Maj

AU - Harmer, Catherine J

AU - Ehrenreich, Hannelore

AU - Kessing, Lars V

PY - 2012

Y1 - 2012

N2 - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

AB - Current pharmacological treatments for depression have a significant treatment-onset-response delay, an insufficient efficacy for many patients and fail to reverse cognitive dysfunction. Erythropoietin (EPO) has neuroprotective and neurotrophic actions and improves cognitive function in animal models of acute and chronic neurodegenerative conditions and in patients with cognitive decline.

U2 - 10.1007/s00213-011-2511-1

DO - 10.1007/s00213-011-2511-1

M3 - Journal article

C2 - 21947319

VL - 219

SP - 687

EP - 698

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -

ID: 48496536